<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02559622</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457ADE02</org_study_id>
    <nct_id>NCT02559622</nct_id>
  </id_info>
  <brief_title>Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab</brief_title>
  <acronym>CARIMA</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory Evaluation of Surrogate Markers of Cardiovascular Risk in Patients With Active Chronic Plaque-type Psoriasis Treated for up to 52 Weeks With Subcutaneous (s.c.) Secukinumab (300 mg or 150 mg).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg
      secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on
      endothelial dysfunction and arterial stiffness after 12 weeks and for up to 52 weeks in
      subjects with chronic plaque-type psoriasis. Furthermore soluble biomarkers were assessed to
      evaluate the influence of secukinumab on cardiovascular risk. Magnetic resonance imaging
      (MRI) was performed in a sub-population to assess the treatment effect on arterial vessel
      wall morphometry in atherosclerosis prone vascular beds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment</measure>
    <time_frame>Week 12</time_frame>
    <description>Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100*[(D maximum - D baseline) / D baseline]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100*[(D maximum - D baseline) / D baseline]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time [m/s]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Insulin at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Adiponectin at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Leptin at Week 4, 12, 24 and 52</measure>
    <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
    <description>Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>300 mg secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg secukinumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by 300 mg secukinumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo until week 12 followed by 300 mg secukinumab every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo followed by 150 mg secukinumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Placebo until week 12 followed by 150 mg secukinumab every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>300 mg secukinumab</description>
    <arm_group_label>300 mg secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo followed by 300 mg secukinumab</description>
    <arm_group_label>Placebo followed by 300 mg secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo followed by 150 mg secukinumab</description>
    <arm_group_label>Placebo followed by 150 mg secukinumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secukinumab</intervention_name>
    <description>150 mg secukinumab</description>
    <arm_group_label>150 mg secukinumab</arm_group_label>
    <other_name>AIN457</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic moderate to severe plaque type psoriasis for at least 6 months prior to
             randomization with a Psoriasis Area and Severity Index (PASI) score ≥ 10 at
             randomization.

          -  Inadequate response, intolerance or contraindication to cyclosporine, methotrexate and
             psoralen plus ultraviolet A light treatment (PUVA) as documented in the patient's
             medical history or reported by the patient or determined by the investigator at
             screening. Relative contraindications such as interference of patient's lifestyle with
             the treatment are accepted.

        Key Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and
             guttata psoriasis) at screening or randomization.

          -  Ongoing use of prohibited psoriasis and non-psoriasis treatments.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33647</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Langenau</city>
        <zip>89129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stade</city>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2015</study_first_submitted>
  <study_first_submitted_qc>September 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2015</study_first_posted>
  <results_first_submitted>April 19, 2017</results_first_submitted>
  <results_first_submitted_qc>April 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 23 centers in Germany.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Secukinumab 300 mg</title>
          <description>Participants were administered with 300 milligrams (mg) secukinumab subcutaneously (s.c.) using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="P2">
          <title>Secukinumab 150 mg</title>
          <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="P3">
          <title>Placebo Followed by 300 mg Secukinumab</title>
          <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="P4">
          <title>Placebo Followed by 150 mg Secukinumab</title>
          <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Secukinumab 300 mg</title>
          <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="B2">
          <title>Secukinumab 150 mg</title>
          <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="B3">
          <title>Placebo Followed by 300 mg Secukinumab</title>
          <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="B4">
          <title>Placebo Followed by 150 mg Secukinumab</title>
          <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="151"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="140"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="12.9"/>
                    <measurement group_id="B2" value="46.0" spread="14.4"/>
                    <measurement group_id="B3" value="43.7" spread="11.4"/>
                    <measurement group_id="B4" value="46.8" spread="13.1"/>
                    <measurement group_id="B5" value="45.2" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment</title>
        <description>Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100*[(D maximum – D baseline) / D baseline]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.</description>
        <time_frame>Week 12</time_frame>
        <population>The analysis was performed in Full analysis set (FAS) population, defined as all participants from the randomized set who received at least one dose of study drug. Here, &quot;Number analyzed&quot; signifies participants evaluable for FMD at Week 12 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Pooled)</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg or 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg or 300 mg secukinumab respectively every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Flow Mediated Dilation (FMD) at Week 12 Followed by Secukinumab 300 mg vs Pooled Placebo Treatment</title>
          <description>Flow Mediated Dilation (FMD) is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100*[(D maximum – D baseline) / D baseline]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 millimeter of mercury (mmHg) for 4.5 minutes and for 4.5 minutes following deflation.</description>
          <population>The analysis was performed in Full analysis set (FAS) population, defined as all participants from the randomized set who received at least one dose of study drug. Here, &quot;Number analyzed&quot; signifies participants evaluable for FMD at Week 12 for each arm, respectively.</population>
          <units>Percentage maximal increase in diameter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.23" spread="5.30"/>
                    <measurement group_id="O2" value="3.65" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2230</p_value>
            <method>ANCOVA</method>
            <param_type>Least Square (LS) mean difference</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52</title>
        <description>FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100*[(D maximum – D baseline) / D baseline]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for FMD at weeks 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Flow Mediated Dilation (FMD) at Week 4, 12, 24 and 52</title>
          <description>FMD is non-invasive method evaluated by Doppler Ultrasound test, to assess endothelial function. FMD was calculated as the percent maximal deviation from the baseline arterial diameter (D):FMD = 100*[(D maximum – D baseline) / D baseline]. Here, arterial diameter (brachial artery) was measured at rest (1 minute), during inflation of the distal cuff to 100 mmHg for 4.5 minutes and for 4.5 minutes following deflation. A positive change in FMD constitutes an improvement in endothelial function.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for FMD at weeks 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>Percentage change in FMD</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" lower_limit="-1.9" upper_limit="0.5"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-2.4" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-1.0" upper_limit="2.5"/>
                    <measurement group_id="O4" value="1.4" lower_limit="-0.8" upper_limit="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-1.1" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.2" upper_limit="1.5"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-2.7" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-2.1" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="35"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-1.9" upper_limit="0.3"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.4" upper_limit="2.4"/>
                    <measurement group_id="O3" value="-0.0" lower_limit="-2.6" upper_limit="2.6"/>
                    <measurement group_id="O4" value="0.9" lower_limit="-1.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="0.8" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.1" lower_limit="0.7" upper_limit="3.4"/>
                    <measurement group_id="O3" value="2.2" lower_limit="-0.5" upper_limit="4.9"/>
                    <measurement group_id="O4" value="1.2" lower_limit="-1.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52</title>
        <description>Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for pulse wave analysis at weeks 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Aortic Augmentation Index at Heart Rate of 75 (AIx-75) at Week 4, 12, 24 and 52</title>
          <description>Pulse wave analysis was performed on the central aortic pressure waveform as derived by SphygmoCor XCEL from the brachial pressure waveform recorded in a partially-inflated blood pressure cuff around the upper arm. The waveform derivation employs a validated generalized transfer function to convert a brachial waveform to a central waveform and has been shown to produce measurement results corresponding to measurements using intra-arterial pressure catheters. The augmentation index is derived from the waveform by determining the percentage of the central pulse pressure during systole due to wave reflection. AIx was heart-rate corrected to calculate the AIx at a heart rate of 75 bpm, i.e. AIx-75.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for pulse wave analysis at weeks 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>Percentage change in Alx-75</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2.8" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-2.0" upper_limit="2.7"/>
                    <measurement group_id="O3" value="1.1" lower_limit="-1.7" upper_limit="3.8"/>
                    <measurement group_id="O4" value="-0.1" lower_limit="-3.0" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-3.0" upper_limit="2.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-1.7" upper_limit="3.8"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-5.4" upper_limit="3.3"/>
                    <measurement group_id="O4" value="-0.1" lower_limit="-3.4" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="0.3" upper_limit="5.6"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-0.6" upper_limit="4.3"/>
                    <measurement group_id="O3" value="1.3" lower_limit="-2.7" upper_limit="5.3"/>
                    <measurement group_id="O4" value="0.7" lower_limit="-2.7" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="-1.5" upper_limit="4.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-2.8" upper_limit="2.7"/>
                    <measurement group_id="O3" value="-1.4" lower_limit="-5.8" upper_limit="2.9"/>
                    <measurement group_id="O4" value="-0.9" lower_limit="-4.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52</title>
        <description>Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time [m/s]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;n&quot; signifies the sum of participants for all repeated measurements during calculation of mean, evaluable for pulse wave velocity (PWV) at Week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pulse Wave Velocity (PWV) at Week 4, 12, 24 and 52</title>
          <description>Regional arterial pulse wave velocity (PWV) was directly related to arterial stiffness and was defined as the time it takes for the blood pressure wave to travel from a proximal site to a distal site (relative to the heart) divided by the distance (PWV = ∆distance/∆time [m/s]). The foot of the arterial pulse wave was being recorded by using the SphygmoCor XCEL device. XCEL simultaneously measures the pressure waveform at the femoral site (using a partially inflated custom blood pressure cuff) and the carotid site (using hand-held applanation tonometry). The foot-to-foot time between the two pressure waveforms was the time interval used in the PWV calculation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;n&quot; signifies the sum of participants for all repeated measurements during calculation of mean, evaluable for pulse wave velocity (PWV) at Week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>meters per second (m/s)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n = 192, 262, 133, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.3" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0" lower_limit="-0.1" upper_limit="0.2"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-0.5" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n = 214, 255, 116, 133)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.2" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.1" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="0.4" lower_limit="0.1" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n = 205, 255, 100, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.1" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.2" upper_limit="0.1"/>
                    <measurement group_id="O3" value="0.2" lower_limit="0.1" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-0.1" lower_limit="-0.5" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n = 191, 228, 115, 101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.3" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.1" upper_limit="0.5"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-0.6" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12</title>
        <description>Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for MRI sub-study at week 12 for each arm, respectively. MRI was applied in a sub-study population of 33 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 12</title>
          <description>Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for MRI sub-study at week 12 for each arm, respectively. MRI was applied in a sub-study population of 33 participants.</population>
          <units>millimeter square (mm^2)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ascending thoracic aorta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.35" lower_limit="-8.23" upper_limit="38.92"/>
                    <measurement group_id="O2" value="5.91" lower_limit="-13.09" upper_limit="24.91"/>
                    <measurement group_id="O3" value="9.92" lower_limit="-58.24" upper_limit="78.08"/>
                    <measurement group_id="O4" value="6.45" lower_limit="-9.26" upper_limit="22.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending thoracic aorta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" lower_limit="-14.18" upper_limit="19.56"/>
                    <measurement group_id="O2" value="-2.94" lower_limit="-13.44" upper_limit="7.57"/>
                    <measurement group_id="O3" value="-4.04" lower_limit="-29.61" upper_limit="21.53"/>
                    <measurement group_id="O4" value="3.16" lower_limit="-13.73" upper_limit="20.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carotid bifurcation left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="-2.72" upper_limit="3.77"/>
                    <measurement group_id="O2" value="-1.08" lower_limit="-3.85" upper_limit="1.69"/>
                    <measurement group_id="O3" value="3.63" lower_limit="-7.82" upper_limit="15.08"/>
                    <measurement group_id="O4" value="1.12" lower_limit="-2.04" upper_limit="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carotid bifurcation right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" lower_limit="-3.60" upper_limit="2.06"/>
                    <measurement group_id="O2" value="1.75" lower_limit="-0.71" upper_limit="4.21"/>
                    <measurement group_id="O3" value="-1.26" lower_limit="-7.64" upper_limit="5.12"/>
                    <measurement group_id="O4" value="-1.07" lower_limit="-4.24" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common carotid left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="-1.64" upper_limit="1.99"/>
                    <measurement group_id="O2" value="1.12" lower_limit="-1.80" upper_limit="4.03"/>
                    <measurement group_id="O3" value="0.69" lower_limit="-5.21" upper_limit="6.59"/>
                    <measurement group_id="O4" value="0.12" lower_limit="-1.91" upper_limit="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common carotid right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" lower_limit="-2.17" upper_limit="1.92"/>
                    <measurement group_id="O2" value="0.30" lower_limit="-2.76" upper_limit="3.36"/>
                    <measurement group_id="O3" value="-0.38" lower_limit="-6.56" upper_limit="5.80"/>
                    <measurement group_id="O4" value="-0.14" lower_limit="-1.60" upper_limit="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal carotid left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" lower_limit="-0.19" upper_limit="7.78"/>
                    <measurement group_id="O2" value="2.09" lower_limit="-0.57" upper_limit="4.75"/>
                    <measurement group_id="O3" value="2.59" lower_limit="-0.58" upper_limit="5.77"/>
                    <measurement group_id="O4" value="-1.74" lower_limit="-4.55" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal carotid right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" lower_limit="-1.90" upper_limit="0.51"/>
                    <measurement group_id="O2" value="0.17" lower_limit="-1.96" upper_limit="2.30"/>
                    <measurement group_id="O3" value="0.68" lower_limit="-3.97" upper_limit="5.33"/>
                    <measurement group_id="O4" value="-1.37" lower_limit="-4.37" upper_limit="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending abdominal aorta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.71" lower_limit="-6.33" upper_limit="23.76"/>
                    <measurement group_id="O2" value="-3.79" lower_limit="-21.90" upper_limit="14.32"/>
                    <measurement group_id="O3" value="4.56" lower_limit="-52.64" upper_limit="61.77"/>
                    <measurement group_id="O4" value="-0.58" lower_limit="-15.51" upper_limit="14.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52</title>
        <description>Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.</description>
        <time_frame>Baseline, Week 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for MRI sub-study at week 52 for each arm, respectively. MRI was applied in a sub-study population of 33 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Wall Area Assessed as a Measure of Total Plaque Burden at Week 52</title>
          <description>Magnetic resonance imaging (MRI) was used to evaluate vessel wall morphometry to determine plaque burden. As a measure of plaque burden, average wall area was computed by subtracting vessel lumen area from total vessel area. Exploratory 3.0 Tesla MRI technique was applied to assess structure and function of the carotid and the aorta. A 2D axial dark blood T1, T2, proton density weighted spin echo based images and time of flight images were acquired from the bilateral carotid arteries as well as the descending aorta.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for MRI sub-study at week 52 for each arm, respectively. MRI was applied in a sub-study population of 33 participants.</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ascending thoracic aorta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.42" lower_limit="-14.93" upper_limit="43.76"/>
                    <measurement group_id="O2" value="3.19" lower_limit="-17.17" upper_limit="23.55"/>
                    <measurement group_id="O3" value="-15.11" lower_limit="-28.15" upper_limit="-2.06"/>
                    <measurement group_id="O4" value="9.54" lower_limit="-14.71" upper_limit="33.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending thoracic aorta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="-13.42" upper_limit="21.37"/>
                    <measurement group_id="O2" value="2.55" lower_limit="-12.23" upper_limit="17.33"/>
                    <measurement group_id="O3" value="-10.14" lower_limit="-34.05" upper_limit="13.77"/>
                    <measurement group_id="O4" value="1.14" lower_limit="-26.76" upper_limit="29.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carotid bifurcation left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="-1.55" upper_limit="6.45"/>
                    <measurement group_id="O2" value="0.64" lower_limit="-3.59" upper_limit="4.88"/>
                    <measurement group_id="O3" value="0.58" lower_limit="-9.03" upper_limit="10.20"/>
                    <measurement group_id="O4" value="2.60" lower_limit="-2.16" upper_limit="7.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carotid bifurcation right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" lower_limit="-6.02" upper_limit="2.74"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-3.62" upper_limit="3.51"/>
                    <measurement group_id="O3" value="-3.23" lower_limit="-9.86" upper_limit="3.40"/>
                    <measurement group_id="O4" value="1.25" lower_limit="-3.92" upper_limit="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common carotid left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" lower_limit="-0.36" upper_limit="3.19"/>
                    <measurement group_id="O2" value="1.21" lower_limit="-1.51" upper_limit="3.93"/>
                    <measurement group_id="O3" value="0.65" lower_limit="-2.82" upper_limit="4.13"/>
                    <measurement group_id="O4" value="1.00" lower_limit="-0.83" upper_limit="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common carotid right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-2.54" upper_limit="2.58"/>
                    <measurement group_id="O2" value="0.23" lower_limit="-2.29" upper_limit="2.75"/>
                    <measurement group_id="O3" value="-0.80" lower_limit="-6.25" upper_limit="4.64"/>
                    <measurement group_id="O4" value="-1.38" lower_limit="-3.33" upper_limit="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal carotid left</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.43" lower_limit="1.21" upper_limit="9.65"/>
                    <measurement group_id="O2" value="3.59" lower_limit="0.59" upper_limit="6.60"/>
                    <measurement group_id="O3" value="1.06" lower_limit="-2.66" upper_limit="4.78"/>
                    <measurement group_id="O4" value="0.33" lower_limit="-5.07" upper_limit="5.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Internal carotid right</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" lower_limit="-2.12" upper_limit="-0.03"/>
                    <measurement group_id="O2" value="0.71" lower_limit="-1.78" upper_limit="3.21"/>
                    <measurement group_id="O3" value="-0.20" lower_limit="-3.89" upper_limit="3.49"/>
                    <measurement group_id="O4" value="0.13" lower_limit="-2.22" upper_limit="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Descending abdominal aorta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.56" lower_limit="-8.37" upper_limit="29.48"/>
                    <measurement group_id="O2" value="-4.36" lower_limit="-17.90" upper_limit="9.19"/>
                    <measurement group_id="O3" value="12.46" lower_limit="-46.12" upper_limit="71.05"/>
                    <measurement group_id="O4" value="11.82" lower_limit="-15.26" upper_limit="38.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52</title>
        <description>High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for hsCRP at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Week 4, 12, 24 and 52</title>
          <description>High sensitivity C-reactive protein (hsCRP), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for hsCRP at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>Milligrams per deciliter (mg/dL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="-0.1"/>
                    <measurement group_id="O3" value="-0.0" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-0.1" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" lower_limit="-0.3" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.3" upper_limit="0.0"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.8" upper_limit="0.1"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-0.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O3" value="0.1" lower_limit="-0.2" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-0.9" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-0.3" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="-0.0"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.8" upper_limit="0.2"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-1.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52</title>
        <description>S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for S100B-protein at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in S-100 Protein B (Total) at Week 4, 12, 24 and 52</title>
          <description>S100 calcium-binding protein B (S100B-protein), a soluble biomarker of systemic inflammation was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for S100B-protein at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>Microgram per Liter (ug/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" lower_limit="-0.0" upper_limit="-0.0"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="-0.0" lower_limit="-0.0" upper_limit="-0.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-0.0" upper_limit="0.0"/>
                    <measurement group_id="O4" value="-0.0" lower_limit="-0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52</title>
        <description>Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for CCL5, MCP-1, MIP-1A and MIP-1B at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Chemokine (C-c Motif) Ligand 5 (CCL5), Monocyte Chemoattractant Protein 1 (MCP-1) and Macrophage Inflammatory Proteins (MIP) 1 Alpha and 1 Beta at Week 4, 12, 24 and 52</title>
          <description>Chemokine (c-c motif) ligand 5 (CCL5), Monocyte chemoattractant protein 1 (MCP-1) and Macrophage inflammatory proteins (MIP) 1 alpha (1A) and 1 beta (1B), soluble biomarkers of systemic inflammation were determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for CCL5, MCP-1, MIP-1A and MIP-1B at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>picograms per milliliter (pg/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CCL5 Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1000" lower_limit="-3106" upper_limit="1094"/>
                    <measurement group_id="O2" value="1649" lower_limit="-597" upper_limit="3895"/>
                    <measurement group_id="O3" value="27.0" lower_limit="-3943" upper_limit="3997"/>
                    <measurement group_id="O4" value="-2000" lower_limit="-5056" upper_limit="281.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCL5 Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2116" lower_limit="-2368" upper_limit="6599"/>
                    <measurement group_id="O2" value="5185" lower_limit="840.3" upper_limit="9530"/>
                    <measurement group_id="O3" value="4393" lower_limit="-1598" upper_limit="10383"/>
                    <measurement group_id="O4" value="3002" lower_limit="-1806" upper_limit="7809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCL5 Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7772" lower_limit="3766" upper_limit="11777"/>
                    <measurement group_id="O2" value="10000" lower_limit="6437" upper_limit="14394"/>
                    <measurement group_id="O3" value="11000" lower_limit="2117" upper_limit="20176"/>
                    <measurement group_id="O4" value="9168" lower_limit="2124" upper_limit="16212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CCL5 Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1515" lower_limit="-2478" upper_limit="5507"/>
                    <measurement group_id="O2" value="3577" lower_limit="-737" upper_limit="7891"/>
                    <measurement group_id="O3" value="-597" lower_limit="-3340" upper_limit="2145"/>
                    <measurement group_id="O4" value="2308" lower_limit="-2558" upper_limit="7175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1 Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" lower_limit="-21.8" upper_limit="7.7"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-17.4" upper_limit="20.2"/>
                    <measurement group_id="O3" value="-25" lower_limit="-57.2" upper_limit="8.0"/>
                    <measurement group_id="O4" value="17.5" lower_limit="-43.1" upper_limit="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1 Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" lower_limit="-1.9" upper_limit="38.7"/>
                    <measurement group_id="O2" value="28.6" lower_limit="-8.4" upper_limit="65.7"/>
                    <measurement group_id="O3" value="11.3" lower_limit="-40.9" upper_limit="63.5"/>
                    <measurement group_id="O4" value="21.5" lower_limit="-18.3" upper_limit="61.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1 Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="-0.6" upper_limit="80.3"/>
                    <measurement group_id="O2" value="241" lower_limit="-203" upper_limit="685.7"/>
                    <measurement group_id="O3" value="-20" lower_limit="-53.9" upper_limit="14.2"/>
                    <measurement group_id="O4" value="33.4" lower_limit="8.3" upper_limit="58.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1 Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" lower_limit="-18.1" upper_limit="62.4"/>
                    <measurement group_id="O2" value="25.4" lower_limit="-21.7" upper_limit="72.6"/>
                    <measurement group_id="O3" value="-11" lower_limit="-60.6" upper_limit="38.6"/>
                    <measurement group_id="O4" value="109" lower_limit="-13.3" upper_limit="230.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1A Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-2.1" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-1.6" upper_limit="1.8"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-2.5" upper_limit="3.5"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-2.3" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1A Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-2.8" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.2" lower_limit="-1.0" upper_limit="5.3"/>
                    <measurement group_id="O3" value="-3.6" lower_limit="-7.0" upper_limit="-0.3"/>
                    <measurement group_id="O4" value="0.9" lower_limit="-3.0" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1A Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-2.9" upper_limit="2.4"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-3.6" upper_limit="2.6"/>
                    <measurement group_id="O3" value="-4.7" lower_limit="-8.4" upper_limit="-1.0"/>
                    <measurement group_id="O4" value="1.7" lower_limit="-1.3" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1A Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="-0.1" upper_limit="8.7"/>
                    <measurement group_id="O2" value="0.8" lower_limit="-3.0" upper_limit="4.5"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-6.0" upper_limit="9.5"/>
                    <measurement group_id="O4" value="20.1" lower_limit="4.7" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1B Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24" lower_limit="-50.8" upper_limit="3.0"/>
                    <measurement group_id="O2" value="-2.6" lower_limit="-24.8" upper_limit="19.5"/>
                    <measurement group_id="O3" value="-16" lower_limit="-57.5" upper_limit="25.8"/>
                    <measurement group_id="O4" value="-20" lower_limit="-54.4" upper_limit="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1B Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-49" lower_limit="-80.9" upper_limit="-16.6"/>
                    <measurement group_id="O2" value="-34" lower_limit="-69.0" upper_limit="1.4"/>
                    <measurement group_id="O3" value="-65" lower_limit="-106" upper_limit="-24.7"/>
                    <measurement group_id="O4" value="-68" lower_limit="-116" upper_limit="-20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1B Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52" lower_limit="-130" upper_limit="26.7"/>
                    <measurement group_id="O2" value="-97" lower_limit="-133" upper_limit="-61.3"/>
                    <measurement group_id="O3" value="-161" lower_limit="-207" upper_limit="-114"/>
                    <measurement group_id="O4" value="79.4" lower_limit="-261" upper_limit="420.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1B Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41" lower_limit="-73.6" upper_limit="-8.6"/>
                    <measurement group_id="O2" value="-59" lower_limit="-89.0" upper_limit="-29.7"/>
                    <measurement group_id="O3" value="-73" lower_limit="-122" upper_limit="-24.2"/>
                    <measurement group_id="O4" value="-31" lower_limit="-109" upper_limit="46.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52</title>
        <description>Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for FPG at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose (FPG) at Week 4, 12, 24 and 52</title>
          <description>Fasting plasma glucose (FPG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for FPG at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-1.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-4.6" upper_limit="1.3"/>
                    <measurement group_id="O3" value="0.9" lower_limit="-4.4" upper_limit="6.1"/>
                    <measurement group_id="O4" value="0.2" lower_limit="-5.2" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="-0.0" upper_limit="7.0"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-4.0" upper_limit="6.2"/>
                    <measurement group_id="O3" value="5.3" lower_limit="-2.2" upper_limit="12.8"/>
                    <measurement group_id="O4" value="-1.5" lower_limit="-7.1" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="1.4" lower_limit="-6.3" upper_limit="9.1"/>
                    <measurement group_id="O3" value="12.1" lower_limit="-10.8" upper_limit="35.0"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-7.7" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="46"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-3.5" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="-3.0" upper_limit="4.4"/>
                    <measurement group_id="O3" value="8.7" lower_limit="-7.5" upper_limit="25.0"/>
                    <measurement group_id="O4" value="0.9" lower_limit="-6.7" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Insulin at Week 4, 12, 24 and 52</title>
        <description>Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Fasting Insulin of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Insulin at Week 4, 12, 24 and 52</title>
          <description>Fasting Insulin, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Fasting Insulin of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>micro units per millilitre (uU/mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-2.0" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-2.3" upper_limit="3.0"/>
                    <measurement group_id="O3" value="-4.7" lower_limit="-17.4" upper_limit="8.1"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-4.8" upper_limit="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-5.1" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-2.7" upper_limit="4.8"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-9.2" upper_limit="4.7"/>
                    <measurement group_id="O4" value="-0.1" lower_limit="-4.9" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-4.1" upper_limit="2.0"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-3.7" upper_limit="4.8"/>
                    <measurement group_id="O3" value="-5.3" lower_limit="-18.5" upper_limit="8.0"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-6.1" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-4.3" upper_limit="3.6"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-1.3" upper_limit="4.2"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-7.5" upper_limit="5.1"/>
                    <measurement group_id="O4" value="3.0" lower_limit="-5.2" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52</title>
        <description>Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for HOMA beta-cell function of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostatic Model Assessment (HOMA) Beta-cell Function at Week 4, 12, 24 and 52</title>
          <description>Homeostatic Model Assessment (HOMA) beta-cell function, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for HOMA beta-cell function of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" lower_limit="-64.7" upper_limit="28.2"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-25.7" upper_limit="25.3"/>
                    <measurement group_id="O3" value="-28" lower_limit="-88.4" upper_limit="33.0"/>
                    <measurement group_id="O4" value="-8.9" lower_limit="-38.5" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16" lower_limit="-74.4" upper_limit="41.5"/>
                    <measurement group_id="O2" value="3.9" lower_limit="-32.0" upper_limit="39.8"/>
                    <measurement group_id="O3" value="-29" lower_limit="-100" upper_limit="41.6"/>
                    <measurement group_id="O4" value="16.6" lower_limit="-20.6" upper_limit="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25" lower_limit="-53.9" upper_limit="3.5"/>
                    <measurement group_id="O2" value="-8.2" lower_limit="-40.2" upper_limit="23.9"/>
                    <measurement group_id="O3" value="-35" lower_limit="-111" upper_limit="40.7"/>
                    <measurement group_id="O4" value="-26" lower_limit="-63.2" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="-40.5" upper_limit="63.5"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-32.6" upper_limit="29.4"/>
                    <measurement group_id="O3" value="9.3" lower_limit="-56.4" upper_limit="75.1"/>
                    <measurement group_id="O4" value="11.6" lower_limit="-26.6" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52</title>
        <description>HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for HOMA insulin resistance of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Homeostatic Model Assessment (HOMA) Insulin Resistance at Week 4, 12, 24 and 52</title>
          <description>HOMA insulin resistance, a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for HOMA insulin resistance of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>Insulin Resistance Index</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.6" upper_limit="1.2"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.9" upper_limit="1.0"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-5.2" upper_limit="3.1"/>
                    <measurement group_id="O4" value="-0.3" lower_limit="-2.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-1.5" upper_limit="1.4"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-0.7" upper_limit="1.8"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-2.5" upper_limit="2.3"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-2.0" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.1" upper_limit="0.6"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-1.3" upper_limit="2.5"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-5.0" upper_limit="2.8"/>
                    <measurement group_id="O4" value="-0.7" lower_limit="-2.2" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-1.2" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-0.3" upper_limit="1.4"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-2.8" upper_limit="2.4"/>
                    <measurement group_id="O4" value="0.7" lower_limit="-1.9" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52</title>
        <description>Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Hemoglobin A1c of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c (Glycated Hemoglobin) at Week 4, 12, 24 and 52</title>
          <description>Hemoglobin A1c (glycated hemoglobin), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Hemoglobin A1c of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>millimole per mole of Haemoglobin</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.5" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-1.0" upper_limit="0.3"/>
                    <measurement group_id="O3" value="-0.7" lower_limit="-2.3" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-1.2" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-0.7" upper_limit="1.5"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-2.2" upper_limit="1.4"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-3.8" upper_limit="1.3"/>
                    <measurement group_id="O4" value="0.1" lower_limit="-0.8" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-1.7" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-1.2" lower_limit="-2.9" upper_limit="0.5"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-2.4" upper_limit="2.1"/>
                    <measurement group_id="O4" value="-1.2" lower_limit="-2.9" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-2.3" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-2.8" lower_limit="-6.1" upper_limit="0.4"/>
                    <measurement group_id="O3" value="-1.9" lower_limit="-4.3" upper_limit="0.6"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-3.0" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52</title>
        <description>Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for SHBG of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Sex Hormone-binding Globulin (SHBG) at Week 4, 12, 24 and 52</title>
          <description>Sex hormone-binding globulin (SHBG), a soluble biomarker of Dysglycemia was determined in fasting blood samples to evaluate the effect of secukinumab on Dysglycemia.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for SHBG of Dysglycemia at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>nanomole per Liter (nmol/L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-1.8" upper_limit="2.1"/>
                    <measurement group_id="O2" value="3.7" lower_limit="-3.0" upper_limit="10.4"/>
                    <measurement group_id="O3" value="4.7" lower_limit="-4.2" upper_limit="13.5"/>
                    <measurement group_id="O4" value="-0.3" lower_limit="-4.0" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-3.4" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.1" lower_limit="-1.8" upper_limit="4.1"/>
                    <measurement group_id="O3" value="3.7" lower_limit="-1.6" upper_limit="9.1"/>
                    <measurement group_id="O4" value="4.1" lower_limit="-0.2" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" lower_limit="-5.1" upper_limit="2.2"/>
                    <measurement group_id="O2" value="3.2" lower_limit="-0.9" upper_limit="7.2"/>
                    <measurement group_id="O3" value="1.7" lower_limit="-2.9" upper_limit="6.3"/>
                    <measurement group_id="O4" value="2.6" lower_limit="-1.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" lower_limit="-10.8" upper_limit="4.6"/>
                    <measurement group_id="O2" value="5.9" lower_limit="-1.3" upper_limit="13.0"/>
                    <measurement group_id="O3" value="-2.6" lower_limit="-14.9" upper_limit="9.6"/>
                    <measurement group_id="O4" value="3.2" lower_limit="-4.3" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52</title>
        <description>Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Triglycerides, Total cholesterol, LDL, HDL, ApoA-1 and ApoB of impaired lipid metabolism at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides, Total Cholesterol, Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB) at Week 4, 12, 24 and 52</title>
          <description>Triglycerides, Total cholesterol, Low density lipoprotein (LDL), High density lipoprotein (HDL), Apolipoprotein A-1 (ApoA-1) and Apolipoprotein B (ApoB), soluble biomarkers of impaired lipid metabolism were determined in fasting blood samples to evaluate the effect of secukinumab on impaired lipid metabolism.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Triglycerides, Total cholesterol, LDL, HDL, ApoA-1 and ApoB of impaired lipid metabolism at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Triglycerides Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-15.5" upper_limit="12.0"/>
                    <measurement group_id="O2" value="6.5" lower_limit="-5.9" upper_limit="18.9"/>
                    <measurement group_id="O3" value="12.7" lower_limit="-12.2" upper_limit="37.7"/>
                    <measurement group_id="O4" value="27.5" lower_limit="-6.6" upper_limit="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" lower_limit="-20.8" upper_limit="2.3"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-9.3" upper_limit="17.3"/>
                    <measurement group_id="O3" value="5.9" lower_limit="-32.4" upper_limit="44.2"/>
                    <measurement group_id="O4" value="2.7" lower_limit="-18.3" upper_limit="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" lower_limit="-16.6" upper_limit="25.8"/>
                    <measurement group_id="O2" value="3.9" lower_limit="-9.1" upper_limit="16.9"/>
                    <measurement group_id="O3" value="32.8" lower_limit="-19.7" upper_limit="85.2"/>
                    <measurement group_id="O4" value="17.1" lower_limit="-2.3" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.6" lower_limit="-44.0" upper_limit="173.2"/>
                    <measurement group_id="O2" value="2.6" lower_limit="-11.7" upper_limit="16.9"/>
                    <measurement group_id="O3" value="-6.0" lower_limit="-54.3" upper_limit="42.3"/>
                    <measurement group_id="O4" value="11.9" lower_limit="-8.6" upper_limit="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="-6.4" upper_limit="7.1"/>
                    <measurement group_id="O2" value="7.1" lower_limit="1.1" upper_limit="13.2"/>
                    <measurement group_id="O3" value="4.8" lower_limit="-3.2" upper_limit="12.8"/>
                    <measurement group_id="O4" value="-2.7" lower_limit="-10.0" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="-3.1" upper_limit="9.4"/>
                    <measurement group_id="O2" value="3.6" lower_limit="-4.1" upper_limit="11.2"/>
                    <measurement group_id="O3" value="10.0" lower_limit="2.8" upper_limit="17.1"/>
                    <measurement group_id="O4" value="-4.2" lower_limit="-11.2" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-5.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-4.9" upper_limit="6.1"/>
                    <measurement group_id="O3" value="7.2" lower_limit="-1.5" upper_limit="16.0"/>
                    <measurement group_id="O4" value="-3.2" lower_limit="-12.0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total cholesterol Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="0.0" upper_limit="15.6"/>
                    <measurement group_id="O2" value="2.3" lower_limit="-5.2" upper_limit="9.9"/>
                    <measurement group_id="O3" value="8.9" lower_limit="2.1" upper_limit="15.7"/>
                    <measurement group_id="O4" value="2.9" lower_limit="-5.9" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="-4.6" upper_limit="6.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="0.8" upper_limit="12.8"/>
                    <measurement group_id="O3" value="5.2" lower_limit="-2.0" upper_limit="12.4"/>
                    <measurement group_id="O4" value="-5.6" lower_limit="-12.1" upper_limit="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="-2.2" upper_limit="7.9"/>
                    <measurement group_id="O2" value="2.7" lower_limit="-4.8" upper_limit="10.1"/>
                    <measurement group_id="O3" value="9.5" lower_limit="3.4" upper_limit="15.5"/>
                    <measurement group_id="O4" value="-5.6" lower_limit="-12.7" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" lower_limit="-8.1" upper_limit="2.7"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-6.9" upper_limit="4.4"/>
                    <measurement group_id="O3" value="1.1" lower_limit="-7.4" upper_limit="9.5"/>
                    <measurement group_id="O4" value="-11" lower_limit="-18.9" upper_limit="-2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="-6.5" upper_limit="9.9"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-8.4" upper_limit="6.5"/>
                    <measurement group_id="O3" value="8.2" lower_limit="1.3" upper_limit="15.0"/>
                    <measurement group_id="O4" value="1.1" lower_limit="-8.4" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-2.6" upper_limit="1.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-1.5" upper_limit="2.2"/>
                    <measurement group_id="O3" value="0.3" lower_limit="-2.3" upper_limit="2.9"/>
                    <measurement group_id="O4" value="-1.3" lower_limit="-4.6" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-2.4" upper_limit="1.6"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-1.8" upper_limit="2.2"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-1.2" upper_limit="3.3"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-4.9" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="-1.5" upper_limit="3.9"/>
                    <measurement group_id="O2" value="0.3" lower_limit="-2.3" upper_limit="2.8"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-3.4" upper_limit="1.3"/>
                    <measurement group_id="O4" value="0.5" lower_limit="-4.1" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-2.1" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-0.5" upper_limit="4.2"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-2.9" upper_limit="2.4"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-4.6" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA-1 Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-5.1" upper_limit="5.7"/>
                    <measurement group_id="O2" value="0.9" lower_limit="-4.0" upper_limit="5.7"/>
                    <measurement group_id="O3" value="7.7" lower_limit="-0.6" upper_limit="15.9"/>
                    <measurement group_id="O4" value="-5.5" lower_limit="-12.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA-1 Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-2.0" upper_limit="10.1"/>
                    <measurement group_id="O2" value="2.4" lower_limit="-1.9" upper_limit="6.8"/>
                    <measurement group_id="O3" value="7.1" lower_limit="1.2" upper_limit="12.9"/>
                    <measurement group_id="O4" value="-3.3" lower_limit="-12.1" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA-1 Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="-0.9" upper_limit="12.0"/>
                    <measurement group_id="O2" value="2.8" lower_limit="-3.0" upper_limit="8.6"/>
                    <measurement group_id="O3" value="3.0" lower_limit="-3.3" upper_limit="9.3"/>
                    <measurement group_id="O4" value="-3.1" lower_limit="-11.3" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoA-1 Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.5" lower_limit="-10.0" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-6.0" lower_limit="-11.6" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-5.5" lower_limit="-14.9" upper_limit="3.9"/>
                    <measurement group_id="O4" value="-13" lower_limit="-22.3" upper_limit="-3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="-2.7" upper_limit="5.6"/>
                    <measurement group_id="O2" value="3.6" lower_limit="0.5" upper_limit="6.6"/>
                    <measurement group_id="O3" value="2.7" lower_limit="-1.1" upper_limit="6.5"/>
                    <measurement group_id="O4" value="-2.5" lower_limit="-7.7" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.6" upper_limit="7.4"/>
                    <measurement group_id="O2" value="3.4" lower_limit="-0.5" upper_limit="7.3"/>
                    <measurement group_id="O3" value="7.4" lower_limit="3.9" upper_limit="11.0"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-7.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-2.8" upper_limit="4.8"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-1.3" upper_limit="5.3"/>
                    <measurement group_id="O3" value="5.6" lower_limit="1.4" upper_limit="9.9"/>
                    <measurement group_id="O4" value="-4.2" lower_limit="-10.7" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ApoB Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="50"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="-2.2" upper_limit="9.6"/>
                    <measurement group_id="O2" value="2.3" lower_limit="-1.8" upper_limit="6.4"/>
                    <measurement group_id="O3" value="6.7" lower_limit="3.0" upper_limit="10.5"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-5.4" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Adiponectin at Week 4, 12, 24 and 52</title>
        <description>Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Adiponectin of impaired lipid metabolism at week 4, 12, 24 and 52 for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Adiponectin at Week 4, 12, 24 and 52</title>
          <description>Adiponectin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Adiponectin of impaired lipid metabolism at week 4, 12, 24 and 52 for each arm, respectively.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.0" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="0.2" lower_limit="-0.4" upper_limit="0.8"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.8" upper_limit="0.5"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-1.2" upper_limit="-0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.1" upper_limit="-0.0"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.7" upper_limit="0.3"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0.1" upper_limit="0.9"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-0.7" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.3" upper_limit="0.9"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.5" upper_limit="0.7"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-0.3" upper_limit="1.8"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-1.6" upper_limit="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.6" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.5" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-1.0" upper_limit="0.2"/>
                    <measurement group_id="O4" value="-1.1" lower_limit="-2.0" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Leptin at Week 4, 12, 24 and 52</title>
        <description>Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
        <time_frame>Baseline, Week 4, 12, 24 and 52</time_frame>
        <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Leptin of impaired lipid metabolism at week 4, 12, 24 and 52 for each arm, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>Secukinumab 300 mg</title>
            <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O2">
            <title>Secukinumab 150 mg</title>
            <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O3">
            <title>Placebo Followed by 300 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
          <group group_id="O4">
            <title>Placebo Followed by 150 mg Secukinumab</title>
            <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Leptin at Week 4, 12, 24 and 52</title>
          <description>Leptin, a soluble biomarker of impaired lipid metabolism was determined in fasting blood samples to evaluate the effect of secukinumab on systemic inflammation.</description>
          <population>The analysis was performed in FAS population. Here, &quot;Number analyzed&quot; signifies participants evaluable for Leptin of impaired lipid metabolism at week 4, 12, 24 and 52 for each arm, respectively</population>
          <units>ng/mL (nanogram per milliliter)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-1.8" upper_limit="0.7"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.1" upper_limit="2.2"/>
                    <measurement group_id="O3" value="-0.2" lower_limit="-1.6" upper_limit="1.2"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-1.2" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.7" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.9" upper_limit="1.2"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-1.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="-0.3" lower_limit="-1.7" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-0.7" upper_limit="1.2"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-0.5" upper_limit="2.4"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-2.8" upper_limit="2.3"/>
                    <measurement group_id="O4" value="-1.4" lower_limit="-4.9" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="51"/>
                    <count group_id="O3" value="26"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" lower_limit="-1.0" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-1.6" upper_limit="0.7"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-3.8" upper_limit="3.0"/>
                    <measurement group_id="O4" value="-2.9" lower_limit="-5.7" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From signing of Informed Consent up to 30 days post last drug treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Secukinumab (300 mg) up to Week 12</title>
          <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab up to 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Secukinumab (150 mg) up to Week 12</title>
          <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab up to 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo up to Week 12</title>
          <description>Participants were administered with placebo up to 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Secukinumab (300 mg) After Week 12</title>
          <description>Participants were administered with 300 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="E5">
          <title>Secukinumab (150 mg) After Week 12</title>
          <description>Participants were administered with 150 mg secukinumab s.c. using pre-filled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="E6">
          <title>Placebo Followed by Secukinumab (300 mg) After Week 12</title>
          <description>Participants were administered with placebo until week 12 followed by 300 mg secukinumab s.c. using prefilled syringe every week for 4 weeks followed by 300 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
        <group group_id="E7">
          <title>Placebo Followed by Secukinumab (150 mg) After Week 12</title>
          <description>Participants were administered with placebo until week 12 followed by 150 mg secukinumab s.c. using prefilled syringe every week for 4 weeks followed by 150 mg secukinumab every 4 weeks until week 48 (last injection).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VESTIBULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>HELICOBACTER INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CLAVICLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>HAEMARTHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>RHEUMATOID ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>VERTEBRAL FORAMINAL STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>OVARIAN CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>UTERINE POLYP</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DRY EYE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>EYE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>BURNING MOUTH SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GLOSSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>INJECTION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ECTHYMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>FUNGAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>GINGIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>HORDEOLUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>IMPETIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>LARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>OTITIS EXTERNA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PULPITIS DENTAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ROOT CANAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SKIN CANDIDA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>BURNS FIRST DEGREE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>BURSA INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>LACERATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>MUSCLE RUPTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SPINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>PYOGENIC GRANULOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SKIN PAPILLOMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>DYSMENORRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>MENOPAUSAL SYMPTOMS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>NASAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>DERMATITIS ATOPIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>INTERTRIGO</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PAPULE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SEBORRHOEIC DERMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single­site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862­-778-­8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

